STAT+: Did the Trump administration just cut Novo a huge financial win?
Source ↗
👁 2
💬 0
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Dr. Oz praised GLP-1s from Eli Lilly’s lab, where he said MFN agreements have drastically cut the price of obesity drugs. Problem is, at least Lilly’s GLP-1s are exempt from the MFN agreements (see below). But who am I to correct people? I incorrectly attr
Dr. Oz praised GLP-1s from Eli Lilly’s lab, where he said MFN agreements have drastically cut the price of obesity drugs. Problem is, at least Lilly’s GLP-1s are exempt from the MFN agreements (see below). But who am I to correct people? I incorrectly attr
Comments (0)